

- 30 -

5 Claims

10 ~~(+) -cis-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolane-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof.~~

15 ~~2. A compound as claimed in Claim 1 substantially free of the corresponding (+)-enantiomer.~~

20 ~~3. A compound as claimed in Claim 1 or Claim 2 wherein the (+)-enantiomer is present in an amount of no more than about 5% w/w.~~

25 ~~4. A compound as claimed in any one of Claims 1 to 3 wherein the (-)-enantiomer is present in an amount of no more than about 2% w/w.~~

30 ~~5. A compound as claimed in any one of Claims 1 to 4 wherein the (+)-enantiomer is present in an amount of less than about 1% w/w.~~

35 ~~6. A compound as claimed in Claim 1 in substantially pure form.~~

40 ~~7. A pharmaceutical composition comprising a compound as claimed in any one of Claims 1 to 6 together with a pharmaceutically acceptable carrier therefor.~~

45 ~~8. A compound as claimed in any one of Claims 1 to 6 for use in therapy.~~

50 ~~9. Use of a compound as claimed in any one of Claims 1 to 6 for the manufacture of a medicament for the treatment of a viral infection.~~

55 ~~10. A method for the treatment of a mammal, including man, suffering from or susceptible to viral infection comprising administration of an effective amount of a compound as claimed in any one of Claims 1 to 6.~~

- 31 -

5
~~and A4~~
11. A method for the preparation of a compound as claimed in any one of Claims 1 to 6 which ~~encompasses~~ separation of the (-)-enantiomer from a mixture also containing the (+)-enantiomer.

10
~~and A4~~
12. A method as claimed in ~~Claim 11~~ wherein the mixture of compounds is a racemic mixture.

15
~~and A5~~
13. A method as claimed in ~~Claim 11 or Claim 12~~ the separation is effected by chiral HPLC.

20
~~and A5~~
14. A method as claimed in ~~Claim 13~~ wherein the HPLC employs as a stationary phase acetylated β -cyclodextrin or cellulose triacetate.

25
~~and A5~~
15. A method as claimed in ~~Claim 11 or Claim 12~~ wherein the separation is effected by enzyme-mediated enantioselective catabolism.

30
~~and A5~~
16. A method is claimed in ~~Claim 15~~ wherein the enzyme is employed in immobilised form.

35
~~and A5~~
17. A method as claimed in ~~Claim 15 or Claim 16~~ wherein the enzyme is cytidine deaminase.

40
~~and A5~~
18. A method as claimed in ~~Claim 15 or Claim 16~~ wherein the enzyme is a 5'-nucleotidase.

45
~~and A5~~
(c)

50
~~and A5~~
acetyl
G3

55
~~and A5~~
acetyl
H3

acetyl
G5

add
G3

add
G3